huCD19/huBCMA Mouse
製品名
huCD19/huBCMA Mouse
製品ID
C001993
系統名
C57BL/6NCya-Cd19em3(hCD19)Tnfrsf17em1(hTNFRSF17)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「huCD19/huBCMA Mouse（カタログ番号C001993）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子別名
BCM, BCMA, CD269, TNFRSF13A, B4, CVID3
染色体
Chr 16, Chr 16
MGI ID
さらに
系統詳細
CD19 is predominantly expressed throughout B-cell development and serves as a critical co-receptor for B-cell receptor (BCR) signal transduction, participating in B-cell development, activation, and differentiation [1]. The TNFRSF17 gene encodes B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor superfamily. BCMA is primarily expressed on mature B cells and plasma cells and acts as a key regulator for maintaining plasma cell survival, antibody secretion, and humoral immunity [2-3].
The huCD19/huBCMA(TNFRSF17) mouse is a dual-gene humanized model obtained by crossing the huCD19 mouse (Catalog No.: C001731) with the huBCMA(TNFRSF17) mouse (Catalog No.: C001630). These two targets cover the critical stages of B-cell development and plasma cell maturation, respectively, together forming an important regulatory network for B-cell immune responses. This model can be used to study the mechanisms of B-cell development, differentiation, and humoral immunity regulation, as well as B-cell-related autoimmune diseases and malignancies such as systemic lupus erythematosus (SLE) and multiple myeloma (MM). It is also suitable for the screening, pharmacodynamic evaluation, safety assessment, and mechanism-of-action studies of anti-CD19 and anti-BCMA dual-target drugs, CAR-T cell therapies, bispecific antibodies, and combination treatment strategies, providing an ideal preclinical research platform for the development of innovative therapies for B-cell-related diseases.
参考文献
Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012 Nov 29;1(1):36.
Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020 Sep 17;13(1):125.
Coquery CM, Erickson LD. Regulatory roles of the tumor necrosis factor receptor BCMA. Crit Rev Immunol. 2012;32(4):287–305.
系統作製戦略
The huCD19/huBCMA mouse is a dual-gene humanized model obtained by crossing the huCD19 mouse (Catalog No.: C001731) with the huBCMA(TNFRSF17) mouse (Catalog No.: C001630).
Figure 1. Gene editing strategy of huCD19 mice. The sequences from the start codon to partial intron 4 of the mouse Cd19 gene were replaced with the sequences from the start codon to partial intron 4 of the human CD19 gene.
Figure 2. Gene editing strategy of huBCMA(TNFRSF17) mice. The mouse Tnfrsf17 endogenous extracellular domain was replaced with the human TNFRSF17 extracellular domain.
適用分野
Research on the regulatory mechanisms of B-cell development, differentiation, and humoral immunity;
Research on B-cell-related autoimmune diseases and malignancies such as systemic lupus erythematosus (SLE) and multiple myeloma (MM);
Research on the screening, pharmacodynamic evaluation, safety evaluation, and mechanism of action of dual-target drugs against CD19 and BCMA, CAR-T cell therapy, bispecific antibodies, and combination therapy strategies.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。